Literature DB >> 8771170

Riboflavin-responsive glutaric aciduria type II presenting as a leukodystrophy.

G Uziel1, B Garavaglia, E Ciceri, I Moroni, M Rimoldi.   

Abstract

The clinical phenotype of multiple acyl-CoA dehydrogenase deficiency in infancy is characterized by recurrent episodes of hypoketotic hypoglycemia and lipid storage myopathy. Brain damage has been described only as a consequence of severe and protracted hypoglycemia. We describe a child who experienced normal physical and psychomotor development until the age of 3 years, who then developed progressive intention tremors, dysarthria, ataxia, and spastic tetraparesis. Episodes of acute metabolic distress were never observed. Magnetic resonance imaging disclosed abnormal signals within the white matter of the brain and cerebellum, suggesting leukodystrophy. Gas chromatography/mass spectrometry analysis revealed abnormally high levels of glutaric acid, dicarboxylic acids, and glycine derivatives in urine. Riboflavin therapy was initiated at 4 years of age, when the patient had already lost control of trunk and head posture. Consistent improvement rapidly occurred after riboflavin supplementation. Glutaric aciduria type II may cause brain damage, in spite of the absence of acute metabolic distress, and should be considered in the differential diagnosis of leukodystrophies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8771170     DOI: 10.1016/0887-8994(95)00187-5

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  5 in total

1.  Mitochondrial Disease.

Authors:  Roser Pons; Darryl C. De Vivo
Journal:  Curr Treat Options Neurol       Date:  2001-05       Impact factor: 3.598

Review 2.  Tools for diagnosis of leukodystrophies and other disorders presenting with white matter disease.

Authors:  Adeline Vanderver
Journal:  Curr Neurol Neurosci Rep       Date:  2005-03       Impact factor: 5.081

Review 3.  Axonal Charcot-Marie-Tooth Disease: from Common Pathogenic Mechanisms to Emerging Treatment Opportunities.

Authors:  Brett A McCray; Steven S Scherer
Journal:  Neurotherapeutics       Date:  2021-10-04       Impact factor: 6.088

4.  Ketone body therapy with D/L-β-hydroxybutyric acid solution in severe MADD.

Authors:  Tobias Fischer; Christiane Elpers; Ulrike Och; Manfred Fobker; Thorsten Marquardt
Journal:  Mol Genet Metab Rep       Date:  2019-06-28

5.  Multi-organ abnormalities and mTORC1 activation in zebrafish model of multiple acyl-CoA dehydrogenase deficiency.

Authors:  Seok-Hyung Kim; Sarah A Scott; Michael J Bennett; Robert P Carson; Joshua Fessel; H Alex Brown; Kevin C Ess
Journal:  PLoS Genet       Date:  2013-06-13       Impact factor: 5.917

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.